Search results for "epitope"

showing 10 items of 455 documents

The Efficacy of Antigen Processing Is Critical for Protection against Cytomegalovirus Disease in the Presence of Viral Immune Evasion Proteins▿

2009

ABSTRACT Cytomegaloviruses (CMVs) code for immunoevasins, glycoproteins that are specifically dedicated to interfere with the presentation of antigenic peptides to CD8 T cells. Nonetheless, the biological outcome is not an immune evasion of the virus, since CD8 T cells can control CMV infection even when immunoevasins are expressed. Here, we compare the processing of a protective and a nonprotective epitope derived from the same viral protein, the antiapoptotic protein M45 in the murine model. The data provide evidence to conclude that protection against CMVs critically depends on antigenic peptides generated in an amount sufficient to exhaust the inhibitory capacity of immunoevasins.

Viral proteinImmunologyAntigen presentationCytomegalovirusBiologyCD8-Positive T-Lymphocytesmedicine.disease_causeMicrobiologyVirusEpitopeEpitopesMiceViral ProteinsImmune systemAntigenVirologyRibonucleotide ReductasesmedicineCytotoxic T cellAnimalsHumansAntigen PresentationAntigen processingVirologyPeptide FragmentsInsect ScienceImmunologyCytomegalovirus InfectionsPathogenesis and ImmunityApoptosis Regulatory Proteins
researchProduct

Immunogenic hotspots in the spacer domain of ADAMTS13 in immune‐mediated thrombotic thrombocytopenic purpura

2021

International audience; Background Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is caused by anti-ADAMTS13 autoantibodies inducing a severe deficiency of ADAMTS13. Epitope mapping studies on samples obtained during acute iTTP episodes have shown that the iTTP immune response is polyclonal, with almost all patients having autoantibodies targeting the spacer domain of ADAMTS13.Objectives To identify the immunogenic hotspots in the spacer domain of ADAMTS13.Patients/methods A library of 11 full-length ADAMTS13 spacer hybrids was created in which amino acid regions of the spacer domain of ADAMTS13 were exchanged by the corresponding region of the spacer domain of ADAMTS1. Next, th…

autoantibodiesADAMTS13 Protein030204 cardiovascular system & hematologyEpitope03 medical and health sciencesEpitopes0302 clinical medicineVon Willebrand factorimmunophenotypinghemic and lymphatic diseasesHumansthrombotic thrombocytopenic purpurachemistry.chemical_classificationbiologyPurpura Thrombotic ThrombocytopenicAutoantibodyHematologyMolecular biologyADAMTS13ADAMTS133. Good healthAmino acidepitope mappingEpitope mappingchemistryPolyclonal antibodiesImmunoglobulin Gbiology.proteinDNA IntergenicAntibody[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Identification of glucan-mannoprotein complexes in the cell wall of Candida albicans using a monoclonal antibody that reacts with a (1,6)- -glucan ep…

1995

The use of a novel monoclonal antibody (mAb) that reacts with (1,6)-beta-glucan has permitted the study of the different covalent linkages between glucan and mannoproteins in the cell wall of Candida albicans. The mAb JRR1 was originally raised by immunization with Zymolyase extracts from C. albicans cell walls, but it soon became apparent that it reacted with a (1,6)-beta-glucan epitope. By using this antibody, we show the existence of glucan-mannoprotein complexes between the (1,6)-beta-glucan epitope recognized by the antibody and cell wall mannoproteins. The topology of the (1,6)-beta-glucan in the cell wall of C. albicans has also been studied.

beta-Glucansmedicine.drug_classFluorescent Antibody Techniquemacromolecular substancesMonoclonal antibodyBinding CompetitiveMicrobiologyChromatography AffinityEpitopeMicrobiologyFungal ProteinsMannansCell wallEpitopesAntigenCell WallPolysaccharidesCandida albicansmedicineCandida albicansGlucansGlucanchemistry.chemical_classificationMembrane GlycoproteinsbiologyTunicamycinAntibodies Monoclonalbiology.organism_classificationCorpus albicanscarbohydrates (lipids)stomatognathic diseaseschemistrybiology.proteinAntibodyMicrobiology
researchProduct

Mucin Glycopeptide-Protein Conjugates - Promising Antitumor Vaccine Candidates

2015

Recent efforts towards the development of synthetic glycopeptide vaccines, which aim at the active immunization of patients against their own tumor tissues, are outlined. To achieve sufficient tumor selectivity, glycopeptides of the tandem repeat region of tumor-associated mucin, MUC1, have been synthesized. Since the endogenous structures usually exert low immunogenicity, these glycopeptide antigens, as B-cell epitopes, were conjugated with immunostimulating components. In the present short review, work is outlined in which the MUC1 B-cell epitope peptides are conjugated with bovine serum albumin (BSA), keyhole limpet hemocyanin (KLH), or tetanus toxoid (TTox). In particular, the synthetic…

biologyChemistryImmunogenicityToxoidchemical and pharmacologic phenomenaGeneral ChemistryPharmacologycomplex mixturesEpitopeGlycopeptideBiochemistryAntigenbiology.proteinAntibodyMUC1Keyhole limpet hemocyaninIsrael Journal of Chemistry
researchProduct

ChemInform Abstract: Mucin Glycopeptide-Protein Conjugates - Promising Antitumor Vaccine Candidates

2015

Recent efforts towards the development of synthetic glycopeptide vaccines, which aim at the active immunization of patients against their own tumor tissues, are outlined. To achieve sufficient tumor selectivity, glycopeptides of the tandem repeat region of tumor-associated mucin, MUC1, have been synthesized. Since the endogenous structures usually exert low immunogenicity, these glycopeptide antigens, as B-cell epitopes, were conjugated with immunostimulating components. In the present short review, work is outlined in which the MUC1 B-cell epitope peptides are conjugated with bovine serum albumin (BSA), keyhole limpet hemocyanin (KLH), or tetanus toxoid (TTox). In particular, the synthetic…

biologyChemistryImmunogenicityToxoidchemical and pharmacologic phenomenaGeneral Medicinecomplex mixturesEpitopeGlycopeptideBiochemistryAntigenbiology.proteinAntibodyKeyhole limpet hemocyaninMUC1ChemInform
researchProduct

Imatinib Mesylate and Nilotinib Affect the MHC-Class I Presentation by Modulating the Proteasomal Processing of Antigenic Peptides.

2009

Abstract Abstract 2169 Poster Board II-146 The tyrosine kinase inhibitors (TKIs) Imatinib mesylate (IM, Gleevec, Glivec) and nilotinib (Tasigna, AMN) are currently used in treatment of chronic myeloid leukaemia (CML). IM has been described to influence the function and differentiation of antigen presenting cells, to inhibit the effector function of T lymphocytes and to decrease the immunogenicity of CML cells by downregulation of tumor associated antigens. In the present study, we analyzed the effect of IM and AMN on proteasomal activity in IM-sensitive or IM/AMN- resistant CML cells as well as in patient samples using a biotinylated active site-directed probe, which, covalently binds and l…

biologyImmunologyCell BiologyHematologyBiochemistryMolecular biologyEpitopeImatinib mesylateProteasomeAntigenBiochemistryNilotinibMHC class Ibiology.proteinmedicineAntigen-presenting cellTyrosine kinasemedicine.drugBlood
researchProduct

Reduced in vitro T-cell responses induced by glutaraldehyde-modified allergen extracts are caused mainly by retarded internalization of dendritic cel…

2012

Summary Although allergen-specific immunotherapy is a clinically effective therapy for IgE-mediated allergic diseases, the risk of IgE-mediated adverse effects still exists. For this reason, chemically modified allergoids have been introduced, which may destroy IgE-binding sites while T-cell activation should be retained. The aim of the study was to analyse the differences between intact allergens and differently modified/aggregated allergoids concerning their internalization as well as T-cell and basophil activation. For this purpose human monocyte-derived immature dendritic cells (DC) were incubated with Phleum pratense or Betula verrucosa pollen extract or with the corresponding allergoi…

biologyT cellmedicine.medical_treatmentmedia_common.quotation_subjectImmunologyImmunotherapybiology.organism_classificationEpitopeIn vitroPhleumchemistry.chemical_compoundBasophil activationmedicine.anatomical_structureBiochemistrychemistrymedicineImmunology and AllergyGlutaraldehydeInternalizationmedia_commonImmunology
researchProduct

Response to Anti CD20 Monoclonal Antibody Rituximab® and Epitope Mapping of Inhibitory Antibodies in Patients with Acquired Haemophilia.

2006

Abstract Introduction: Acquired haemophilia (AcH) is associated with the development of polyclonal autoantibodies against FVIII, which affect directly the A2 or C2 domain of the FVIII molecule. Immunomodulatory therapy regimes to normalize FVIII levels and to eliminate the inhibitor are essential options in the treatment of patients (pts) with AcH. The aims of the present study were to investigate the response to Rituximab® and to localize the inhibitor epitopes on the FVIII domains. Patients and Methods: In 5 pts with AcH (2 females,3 males; age: 64–81 yrs) the inhibitor titers ranged from 9 to 156 BU and the FVIII activities from <1 % to 6 %. Rituximab® was administered once weekly…

business.industrymedicine.drug_classImmunologyAutoantibodyCell BiologyHematologyMonoclonal antibodyBiochemistryEpitopeTiterEpitope mappingMedian follow-upPrednisonehemic and lymphatic diseasesImmunologyMedicineRituximabbusinessmedicine.drugBlood
researchProduct

Synthetic Glycopeptides for the Development of Antitumour Vaccines

2003

Glycoproteins of tumour cells often are aberrantly glycosylated. In its tumour-associated form, the epithelial mucin MUC1 carries short saccharide structures such as TN, T, sialyl-TN, and sialyl-T antigens. Due to the incomplete saccharide components, peptide epitopes of the backbone become accessible to the immune system. For the construction of synthetic antitumour vaccines, glycopeptides have been synthesized which contain tumour-associated saccharide antigens and peptide sequences from the tandem repeat portion of MUC1. In the synthesis of these glycopeptides, preformed glycosyl–amino acid building blocks are applied in solution- or solid-phase strategies. Examples are given for the use…

chemistry.chemical_classificationAntigenBiochemistryChemistryImmunogenicityPeptideGeneral ChemistryGlycoproteinLinkerMUC1EpitopeGlycopeptideAustralian Journal of Chemistry
researchProduct

Improved detection of melanoma antigen-specific T cells expressing low or high levels of CD8 by HLA-A2 tetramers presenting a Melan-A/Mart-1 peptide …

2001

MHC class I tetramers containing peptide epitopes are sensitive tools for detecting antigen-specific CD8(+) T-cell responses. We demonstrate here that binding of HLA-A2 tetramers to CD8(+) T cells specific for the melanoma-associated antigen Melan-A/MART-1 can be fine-tuned by altering either the bound peptide epitope or residues in the alpha 3 domain of HLA-A2, which is important for CD8 binding. Antigen-specific T cells expressing high levels of CD8 could be detected using HLA-A2 tetramers containing the peptide AAGIGILTV, an epitope which is naturally processed and presented from Melan-A/MART-1. In contrast, low CD8-expressing, antigen-specific T cells could be detected efficiently only …

chemistry.chemical_classificationCancer ResearchbiologyT-cell receptorPeptideMHC restrictionVirologyMolecular biologyEpitopeOncologychemistryAntigenMHC class IMART-1 Antigenbiology.proteinCD8International Journal of Cancer
researchProduct